Sorry, Jimmy, but I don’t have any real information to offer. I know
lapatinib has been studied in lung cancer but was essentially given up
on by its manufacturer, GlaxoSmithKline, for lung cancer several years
ago. I’m sure it’s involved in a few trials here and there, but not a
critical mass of research or clinical interest in it. And I don’t know
enough about nimotuzumab to comment.